Suggested remit: To appraise the clinical and cost effectiveness tovorafenib within its marketing authori-sation treating people aged 6 months and over with relapsed or refractory paediatric low-grade glioma (LGG) with a BRAF fusion or rearrangement or BRAF V600 mutation.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6557
Provisional Schedule
- Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6557:
- 11 July 2025 - 08 August 2025
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email [email protected]
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 11 July 2025 | In progress. Scoping commencing |
| 07 February 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual